ANIP - ANI Pharmaceuticals Non-GAAP EPS of $1.28 beats by $0.61 revenue of $116.5M beats by $16.64M
2023-08-09 06:53:30 ET
- ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q2 Non-GAAP EPS of $1.28 beats by $0.61 .
- Revenue of $116.5M (+57.6% Y/Y) beats by $16.64M .
- Bright Health is revising its 2023 financial outlook to reflect the movement of our California Medicare Advantage business to Held for Sale accounting. Bright Health’s Enterprise Revenue is expected to be between $1.15 billion and $1.2 billion
- On a segment basis, Care Solutions Revenue is expected to be between $900 million and $925 million, while Care Delivery Revenue is expected to be between $250 million and $275 million
- Enterprise Adjusted Operating Cost Ratio is expected to be between 17.5% and 18.5%
- Bright Health expects to be Adjusted EBITDA profitable in 2023
For further details see:
ANI Pharmaceuticals Non-GAAP EPS of $1.28 beats by $0.61, revenue of $116.5M beats by $16.64M